For this purpose, Vogelstein and his colleagues developed a new bispecific antibody H2-scDb, with one arm binding to a T-cell receptor and the other recognizing the mutant p53 (R175) peptide-HLA complex on the cancer cell surface [104]. This evidence concerns the gene TP53 and cancer.